#United States #New York #Pomerantz LLP #SEC Investigation #Valneva SE

Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE

The Pomerantz Law Firm has announced an investigation concerning claims made by investors of Valneva SE, a biotechnology company known for its vaccine developments, particularly in relation to its chikungunya virus vaccine, IXCHIQ. As reported on April 22, 2025, the investigation was prompted by a troubling notice from the U.S. Centers for Disease Control and Prevention (CDC) posted on February 25, 2025.

CDC's Warnings and Stock Price Impact

The CDC's announcement mentioned that it was investigating incidents of cardiac and neurological events that occurred following vaccinations with IXCHIQ among individuals aged 65 and over. This critical statement raised immediate concerns among investors, leading to media coverage that heavily impacted Valneva's stock performance. In a span of just four trading sessions after the CDC's revelation, Valneva's American Depositary Receipt (ADR) price plummeted by $1.06, signaling a dramatic decline of 13.57%, closing at $6.75 on February 28, 2025.

Investigation Focus

The central issue under scrutiny by Pomerantz LLP revolves around whether Valneva and its officers or directors engaged in securities fraud or other unlawful business practices. This investigation opens the door for investors who may have suffered losses due to these developments to potentially form a class action lawsuit against the company.

For investors in Valneva looking to get involved, they are encouraged to reach out to Danielle Peyton at Pomerantz LLP. This law firm has a long-standing reputation in corporate and securities class action litigation, having been founded by Abraham L. Pomerantz, who was pivotal in establishing the legal framework around securities class actions. Even after more than 85 years, Pomerantz continues to champion the cause of victims impacted by fraudulent activities and corporate misconduct.

The Legal Landscape

One of the critical aspects of the investigation is how regulatory bodies like the CDC might influence public perception and investor confidence in pharmaceutical companies, especially during sensitive periods when adverse reactions are identified post-vaccination. The law firm emphasizes its commitment to pursue justice and recovery for those affected, taking into account the unique challenges that investors face in volatile markets influenced by sudden public health concerns.

As a leading firm in this field, Pomerantz has a history of securing significant damages for class members, highlighting its vigorous enforcement of investors' rights. This proactive approach is necessary, especially in an era where transparency and accountability in the healthcare sector are paramount.

Conclusion

Valneva SE represents a compelling case in the intersection of public health, corporate responsibility, and investor rights. With Pomerantz LLP spearheading the investigation, affected investors may find a pathway to not only recover their losses but also contribute to a broader dialogue about safety and accountability in the vaccine industry.

Investors interested in learning more about the proceedings or who wish to join the class action are once again urged to contact Pomerantz LLP for further assistance. The firm's professional network, spanning major cities globally, ensures comprehensive legal expertise and advocacy in the pursuit of justice for investors.